37 articles
Shore discusses the FDA approval of NUBEQA® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
CEO of On Target Laboratories, Martin Low, discusses On Target's development of two new drugs: OTL78, for the treatment of prostate cancer that selectiv...
Michael Koch, MD, discusses the development of On Target Laboratories' new drug OTL-78 which targets and binds to cancerous cells, causing them to fluor...
Robotic-assisted prostatectomy is providing the same results for urinary and erectile function as open prostatectomy. Learn more on Health Professional Radio.
Bruce Brown, M.D., discusses the importance of active surveillance in prostate cancer and Dendreon's new ProVent trial with PROVENGE (sipuleucel-T) that...
A DNA (spit) test for prostate cancer is being developed by a group of international scientists based at the Institute of Cancer Research (ICR) in London.
Bruce Brown, M.D., a certified urologist and SVP of Medical at Dendreon Pharmaceuticals LLC discusses PROVENGE (sipuleucel-T), the first FDA approved im...
According to a new study that was published in the Medical Journal of Australia, around three-quarters of Australian men who are diagnosed with low risk...
is a partner at the Michigan Institute of Urology, P.C. Learn more on Health Professional Radio.
Guest: Andrew Hilew Presenter: Neal Howard Guests Bio: Andrew Hilew, a practicing lawyer, was shocked when he was diagnosed with prostate cancer in 2009.